This project investigates the crosstalk between glucocorticoid receptor (GR) signaling and RAS oncogene pathways in non-small cell lung cancer (NSCLC) using patient-derived organoid models. Researchers will explore how GR-RAS interactions influence the tumor microenvironment, particularly stromal and immune cell modulation, contributing to tumor progression and therapy resistance. Utilizing multiomics and complex co-culture assembloids, this project aims to identify biomarkers predictive of treatment response and to develop novel strategies for drug repurposing and combination therapies targeting GR-RAS axis-mediated resistance mechanisms.